Articles

Find an Article

Filter articles

Applied Filters

Showing 31 to 40 of 136 results

LSIPR 50 2018: Brian Anderson

US22-08-2018

Brian Anderson was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

Combination SPCs: shaken and stirred

UK14-08-2018Joel Beevers and Michael Pears

Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate.

Hatch-Waxman amendment: a Hobson’s choice

US08-08-2018Janine Carlan

If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.

LSIPR 50 2018: Patrick Leahy

US23-07-2018

Patrick Leahy was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Raymond Chen and Kathleen O’Malley

US20-07-2018

Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for​ ​their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Scott Gottlieb

US19-07-2018

Scott Gottlieb was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Levelling the medicines playing field

India02-07-2018

Speaking to LSIPR Leena Menghaney, regional head of Médecins Sans Frontières’ Access Campaign in South Asia, explains the importance of a balanced IP policy in fostering healthy generic competition.

Protecting patients, and patents

Canada, Indonesia, Singapore04-06-2018

Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.

Getting into the biosimilars action

US06-03-2018Henk Heus and Ellen Sherin

The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.

From London to Amsterdam: what the EMA’s move means for medicines regulation

EU15-12-2017Rachel Bradley

While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.

Showing 31 to 40 of 136 results

LSIPR